FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W183895172> ?p ?o ?g. }

• W183895172 abstract "Objective: The objective of this selective EBM review is to determine whether or not starting antiretroviral therapy (ART) in HIV positive adults with CD4 cell count of 500 cells/μl. In 2010, the CDC estimated the lifetime cost of HIV treatment to be nearly $380,000. TB treatment involves multiple medications and lengthy treatment and can range from $101, 553 for hospital treatments to $27,490 with less expensive medicines in the US. Data were unavailable as to the combined cost of HIV positive persons co infected with TB. Both TB and HIV are serious conditions, but when they are co-infecting a patient it can become a lethal combination. The WHO estimates that at least 33% of the 34 million diagnosed HIV positive are infected with TB, and that population is up to 34 times more likely to progress from latent to active TB than an HIV negative population. TB continues to be a significant cause Erlien; ART Timing in TB therapy 3 of death in HIV positive adults, up to 25% according to the WHO. The current 2009 WHO guideline is to start ART as soon as possible after TB therapy is started without regard to the patient’s CD4+ T-cell count. It has been proposed that starting ART early (within four weeks) of TB treatment can be beneficial in reducing mortality rates in HIV positive patients with any CD4 cell counts, but more effective in patients with lower CD4 cell counts. ART is important in HIV patients with active TB infections but there is concern with starting ART during the induction phase which can cause a high pill burden, drug interactions and an increased likelihood of immune reconstitution inflammatory syndrome (IRIS) when both treatments are combined. Objective The objective of this selective EBM review is to determine whether or not starting HIV therapy within the first 4 weeks of a positive TB test in adults with a CD4 cell count of <300 cells/μl has a lower mortality rate than waiting to start treatment until after 4 weeks of TB" @default.
• W183895172 created "2016-06-24" @default.
• W183895172 creator A5021200878 @default.
• W183895172 date "2013-01-01" @default.
• W183895172 modified "2023-09-26" @default.
• W183895172 title "Is Starting Antiretroviral Therapy (ART) in HIV Positive Adults with CD4 Cell Count of /μl within Four Weeks of Initiating New Tuberculosis (TB) Therapy More Effective in Reducing Mortality Rates than Starting ART Four Weeks or Later after Initiating New TB Therapy?" @default.
• W183895172 cites W2049576942 @default.
• W183895172 cites W2067100208 @default.
• W183895172 cites W2117344292 @default.
• W183895172 hasPublicationYear "2013" @default.
• W183895172 type Work @default.
• W183895172 sameAs 183895172 @default.
• W183895172 citedByCount "0" @default.
• W183895172 crossrefType "journal-article" @default.
• W183895172 hasAuthorship W183895172A5021200878 @default.
• W183895172 hasConcept C126322002 @default.
• W183895172 hasConcept C142462285 @default.
• W183895172 hasConcept C142724271 @default.
• W183895172 hasConcept C179755657 @default.
• W183895172 hasConcept C187212893 @default.
• W183895172 hasConcept C203014093 @default.
• W183895172 hasConcept C2780182762 @default.
• W183895172 hasConcept C2781069245 @default.
• W183895172 hasConcept C2908647359 @default.
• W183895172 hasConcept C2993143319 @default.
• W183895172 hasConcept C3013748606 @default.
• W183895172 hasConcept C71924100 @default.
• W183895172 hasConcept C99454951 @default.
• W183895172 hasConceptScore W183895172C126322002 @default.
• W183895172 hasConceptScore W183895172C142462285 @default.
• W183895172 hasConceptScore W183895172C142724271 @default.
• W183895172 hasConceptScore W183895172C179755657 @default.
• W183895172 hasConceptScore W183895172C187212893 @default.
• W183895172 hasConceptScore W183895172C203014093 @default.
• W183895172 hasConceptScore W183895172C2780182762 @default.
• W183895172 hasConceptScore W183895172C2781069245 @default.
• W183895172 hasConceptScore W183895172C2908647359 @default.
• W183895172 hasConceptScore W183895172C2993143319 @default.
• W183895172 hasConceptScore W183895172C3013748606 @default.
• W183895172 hasConceptScore W183895172C71924100 @default.
• W183895172 hasConceptScore W183895172C99454951 @default.
• W183895172 hasLocation W1838951721 @default.
• W183895172 hasOpenAccess W183895172 @default.
• W183895172 hasPrimaryLocation W1838951721 @default.
• W183895172 hasRelatedWork W1588780716 @default.
• W183895172 hasRelatedWork W1832912444 @default.
• W183895172 hasRelatedWork W2028050692 @default.
• W183895172 hasRelatedWork W2151787161 @default.
• W183895172 hasRelatedWork W2183276925 @default.
• W183895172 hasRelatedWork W2264763257 @default.
• W183895172 hasRelatedWork W2329884323 @default.
• W183895172 hasRelatedWork W2340212196 @default.
• W183895172 hasRelatedWork W2342437949 @default.
• W183895172 hasRelatedWork W2408296329 @default.
• W183895172 hasRelatedWork W2428244928 @default.
• W183895172 hasRelatedWork W2602281718 @default.
• W183895172 hasRelatedWork W2606498452 @default.
• W183895172 hasRelatedWork W2738944752 @default.
• W183895172 hasRelatedWork W2782888254 @default.
• W183895172 hasRelatedWork W2888814629 @default.
• W183895172 hasRelatedWork W2895597029 @default.
• W183895172 hasRelatedWork W2949728198 @default.
• W183895172 hasRelatedWork W3000255965 @default.
• W183895172 hasRelatedWork W2436343823 @default.
• W183895172 isParatext "false" @default.
• W183895172 isRetracted "false" @default.
• W183895172 magId "183895172" @default.
• W183895172 workType "article" @default.